293 related articles for article (PubMed ID: 3104022)
1. Species differences in pharmacokinetics and drug teratogenesis.
Nau H
Environ Health Perspect; 1986 Dec; 70():113-29. PubMed ID: 3104022
[TBL] [Abstract][Full Text] [Related]
2. Teratogenicity of isotretinoin revisited: species variation and the role of all-trans-retinoic acid.
Nau H
J Am Acad Dermatol; 2001 Nov; 45(5):S183-7. PubMed ID: 11606951
[TBL] [Abstract][Full Text] [Related]
3. Low teratogenicity of 13-cis-retinoic acid (isotretinoin) in the mouse corresponds to low embryo concentrations during organogenesis: comparison to the all-trans isomer.
Kraft JC; Kochhar DM; Scott WJ; Nau H
Toxicol Appl Pharmacol; 1987 Mar; 87(3):474-82. PubMed ID: 3470977
[TBL] [Abstract][Full Text] [Related]
4. Single versus multiple dose administration of all-trans-retinoic acid during organogenesis: differential metabolism and transplacental kinetics in rat and rabbit.
Collins MD; Tzimas G; Bürgin H; Hummler H; Nau H
Toxicol Appl Pharmacol; 1995 Jan; 130(1):9-18. PubMed ID: 7839374
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison.
Hendrickx AG; Nau H; Binkerd P; Rowland JM; Rowland JR; Cukierski MJ; Cukierski MA
Teratology; 1988 Oct; 38(4):329-45. PubMed ID: 3149039
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison.
Carney EW; Scialli AR; Watson RE; DeSesso JM
Birth Defects Res C Embryo Today; 2004 Dec; 72(4):345-60. PubMed ID: 15662707
[TBL] [Abstract][Full Text] [Related]
7. Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo.
Nau H; Scott WJ
Nature; 1986 Sep 18-24; 323(6085):276-8. PubMed ID: 3093888
[TBL] [Abstract][Full Text] [Related]
8. Maternal toxicokinetics, metabolism, and embryo exposure following a teratogenic dosing regimen with 13-cis-retinoic acid (isotretinoin) in the cynomolgus monkey.
Hummler H; Hendrickx AG; Nau H
Teratology; 1994 Sep; 50(3):184-93. PubMed ID: 7871482
[TBL] [Abstract][Full Text] [Related]
9. Distribution, teratogenicity, and embryonic delivered dose of retinoid Ro 23-9223.
Willhite CC; Lovey A; Eckhoff C
Toxicol Appl Pharmacol; 2000 Apr; 164(2):171-5. PubMed ID: 10764630
[TBL] [Abstract][Full Text] [Related]
10. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
Ornoy A
Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.
Nau H; Hauck RS; Ehlers K
Pharmacol Toxicol; 1991 Nov; 69(5):310-21. PubMed ID: 1803343
[TBL] [Abstract][Full Text] [Related]
13. Embryonic delivered dose of isotretinoin (13-cis-retinoic acid) and its metabolites in hamsters.
Eckhoff C; Willhite CC
Toxicol Appl Pharmacol; 1997 Sep; 146(1):79-87. PubMed ID: 9299599
[TBL] [Abstract][Full Text] [Related]
14. Selective agonists of retinoic acid receptors: comparative toxicokinetics and embryonic exposure.
Arafa HM; Elmazar MM; Hamada FM; Reichert U; Shroot B; Nau H
Arch Toxicol; 2000 Jan; 73(10-11):547-56. PubMed ID: 10663386
[TBL] [Abstract][Full Text] [Related]
15. Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid.
Tzimas G; Nau H; Hendrickx AG; Peterson PE; Hummler H
Teratology; 1996 Nov; 54(5):255-65. PubMed ID: 9035347
[TBL] [Abstract][Full Text] [Related]
16. Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance.
Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW
Drug Metab Dispos; 2000 Jul; 28(7):845-56. PubMed ID: 10859159
[TBL] [Abstract][Full Text] [Related]
17. Developmental toxicity of valproic acid.
Cotariu D; Zaidman JL
Life Sci; 1991; 48(14):1341-50. PubMed ID: 2008152
[TBL] [Abstract][Full Text] [Related]
18. Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model.
Mast TJ; Cukierski MA; Nau H; Hendrickx AG
Toxicology; 1986 May; 39(2):111-9. PubMed ID: 3085290
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic determinants of embryotoxicity in rats associated with organic acids.
Scott WJ; Collins MD; Nau H
Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):97-101. PubMed ID: 7737049
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.
Lewandowski C; Klug S; Nau H; Neubert D
Arch Toxicol; 1986 Apr; 58(4):239-42. PubMed ID: 3087328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
